Eagle Pharmaceuticals announces David Pernock as president and chief commercial officer.
Eagle Pharmaceuticals, Inc. announced that David Pernock will join Eagle as president and chief commercial officer, effective January 2017. Pernock will be responsible for all commercial strategy and execution for Eagle’s growing product portfolio, including the launch of expanded indications for Ryanodex for exertional heat stroke (“EHS”) and drug induced hyperthermia, if approved by the Food and Drug Administration (FDA). He will report to Scott Tarriff, Eagle’s chief executive officer.
“David has a distinguished track record as a leader in the pharmaceutical sector. During his tenure at GlaxoSmithKline, he brought multiple blockbuster drugs to market and led strategic direction and operational success across diverse businesses, and most recently served as the CEO of a publicly-traded gene therapy biotechnology company,” Tarriff said in a press statement. “His appointment fortifies our management team and underscores Eagle’s commitment to the success of our growing portfolio and the opportunities we see in our pipeline, such as the label expansion of Ryanodex for the treatment of exertional heat stroke, a near-term opportunity, if approved by the FDA. This would be a very significant product launch for the company, and we are thrilled to have someone of David’s caliber to lead its success.”
Pernock commented: “If approved, Ryanodex for EHS would address the needs of new patient populations for whom no pharmaceutical treatment options are currently available. We view the potential launch of Ryanodex as a very significant opportunity and are committed to allocating the resources required to help ensure a successful commercial launch.”
Pernock has been a member of Eagle’s board of directors since April 2015. He will relinquish his Eagle board position effective January 2017, in connection with his new role.
(Source: Business Wire)
